These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18474492)

  • 1. Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
    Wright D; Rodriguez A; Godofsky E; Walmsley S; Labriola-Tompkins E; Donatacci L; Shikhman A; Tucker E; Chiu YY; Chung J; Rowell L; Demasi R; Graham N; Salgo M
    HIV Clin Trials; 2008; 9(2):73-82. PubMed ID: 18474492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
    Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
    AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J; Arastéh K; Clotet B; Cohen C; Cooper DA; Delfraissy JF; Eron JJ; Henry K; Katlama C; Kuritzkes DR; Lalezari JP; Lange J; Lazzarin A; Montaner JS; Nelson M; O' Hearn M; Stellbrink HJ; Trottier B; Walmsley SL; Buss NE; Demasi R; Chung J; Donatacci L; Guimaraes D; Rowell L; Valentine A; Wilkinson M; Salgo MP
    AIDS Patient Care STDS; 2007 Aug; 21(8):533-43. PubMed ID: 17711378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
    Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
    Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
    Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B
    Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).
    Lalezari JP; Saag M; Walworth C; Larson P
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):805-13. PubMed ID: 18507525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
    Ruane P; Alas B; Ryan R; Perniciaro A; Witek J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1215-9. PubMed ID: 21083412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
    Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
    New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to enfuvirtide and its impact on treatment efficacy.
    Rockstroh J; Dejesus E; Donatacci L; Wat C; Bertasso A; Labriola-Tompkins E; Shikhman A; Atkins B; Guimaraes D; Wilkinson M; Thommes J; Rowell L; Demasi R; Salgo M
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):141-8. PubMed ID: 18240965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
    Bonora S; Calcagno A; Cometto C; Fontana S; Aguilar D; D'Avolio A; Gonzalez de Requena D; Maiello A; Dal Conte I; Lucchini A; Di Perri G
    Infection; 2012 Feb; 40(1):69-75. PubMed ID: 22135137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of benefit of 3-month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: the INNOVE study.
    Morand-Joubert L; Ghosn J; Delaugerre C; Giffo B; Solas C; Samri A; Pinta A; Triglia A; Raffi F;
    J Med Virol; 2012 Nov; 84(11):1710-8. PubMed ID: 22997073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
    Wheeler DA; Lalezari JP; Kilby JM; Wheat J; Delehanty J; DeMasi R; Patel I; Salgo M
    J Clin Virol; 2004 Jun; 30(2):183-90. PubMed ID: 15125875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
    J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.